

## ASX ANNOUNCEMENT

25 March 2022

VIRTUS HEALTH LIMITED (ASX: VRT)

### Foreign Investment Review Board approval received for CapVest transaction

---

Virtus Health Limited ("Virtus", ASX: VRT) has been advised by CapVest Partners LLP ("CapVest") that it has received written confirmation from the Foreign Investment Review Board ("FIRB") that the Commonwealth Government has no objections under the *Foreign Acquisitions and Takeovers Act 1975* (Cth) to the proposed acquisition of Virtus by CapVest-controlled entities by way of scheme of arrangement ("Scheme") and a concurrent off-market takeover offer ("Takeover Offer"), as announced on 14 March 2022.

This confirmation satisfies the FIRB condition in the Transaction Implementation Deed between Virtus and CapVest dated 13 March 2022 in respect of both the Scheme and Takeover Offer. The Scheme and Takeover Offer remain subject to other conditions which are set out in full in the Transaction Implementation Deed.

As previously announced, Virtus expects to send a Transaction Booklet to Virtus shareholders during May 2022 in respect of the Scheme and Takeover Offer. Following this, a Scheme meeting is expected to be held in June 2022 for Virtus shareholders to vote on the Scheme.

Virtus shareholders do not need to take any action at this stage and the Board will keep the market informed of any material developments in accordance with its continuous disclosure obligations.

This announcement is authorised by the board of directors of the company.

**- ENDS -**

#### Further information:

##### Investor Enquiries:

Matt Prior  
CFO, Virtus Health  
+61 (0)498 003 973  
matthew.prior@virtushealth.com.au

##### Media Enquiries:

Peter Brookes  
Citadel Magnus  
+61 (0)407 911 389  
pbrookes@citadelmagnus.com

**Virtus Health Limited** (ASX:VRT) brings together leading clinicians, scientists, researchers and support staff to provide the very best in fertility care and related specialised diagnostic and day hospital services. We have developed one of the most successful ARS collaborations in the world. With 126 of the world's leading fertility specialists supported by over 1300 professional staff, we are the largest network and provider of fertility services in Australia, Ireland and Denmark, Singapore and UK.